首页 | 本学科首页   官方微博 | 高级检索  
     


High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer
Authors:Ken-ichi Fujita
Affiliation:1. Department of Medical Oncology, International Medical Center-Comprehensive Cancer Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan;2. Institute of Molecular Oncology, Showa University, 1-5-8 Hatanodai, Tokyo 142-8555, Japan;1. Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Tokyo 142-8666, Japan;2. Department of Respirology, National Hospital Organization, Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo 204-8585, Japan; Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Tokyo 142-8666, Japan; Department of Medical Oncology, International Medical Center-Comprehensive Cancer Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan;1. Department of Medical Oncology, International Medical Center-Comprehensive Cancer Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan;2. Institute of Molecular Oncology, Showa University, 1-5-8 Hatanodai, Tokyo 142-8555, Japan;3. Department of Medical Oncology, Showa University School of Medicine, 1-5-8 Hatanodai, Tokyo 142-8666, Japan
Abstract:
Keywords:Erlotinib   Interstitial lung disease   Pharmacokinetics   High exposure   ABCG2   Polymorphism
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号